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ABSTRACT 
Background. Although, heart failure with preserved ejection fraction (HFpEF) is considered a 
disease of the elderly, younger patients are not spared from this syndrome. 
Objectives: We therefore investigated the associations between age, clinical characteristics and 
outcomes in patients with HFpEF. 
Methods. Using data on patients with LVEF≥45% from three large HFpEF trials (TOPCAT, I-
Preserve and CHARM-Preserved), we categorized patients according to age: ≤55 years (n=522), 
56-64 years (n=1678), 65-74 (n=3402), 75-84 (n=2461) and ≥85 years (n=398). We compared 
clinical and echocardiographic characteristics, as well as mortality and hospitalization rates, 
mode of death and quality-of-life across age categories. 
Results. Younger patients (≤55 years) with HFpEF were more often obese, non-white men, 
while older patients with HFpEF were more often white women with a higher prevalence of 
atrial fibrillation, hypertension and CKD (eGFR<60 ml/min/1.73m2). Despite fewer 
comorbidities, younger patients had worse quality of life compared to older patients (≥85 years). 
Compared to patients ≤55 years, patients ≥85 years had higher mortality (hazard ratio: 6.9; 
95%CI 4.2-11.4). However, among patients who died, sudden death (SD) was, proportionally, 
the most common mode of death (P <0.001) in patients ≤55 years. In contrast, older patients 
(≥85) died more often of non-cardiovascular causes (34% versus 20% in patients ≤55 years; 
P<0.001).  
Conclusion. Compared to the elderly, younger patients with HFpEF were less likely to be white, 
more frequently obese men who die more often of CV causes, particularly SD. In contrast, 
elderly patients with HFpEF have more comorbidities and die more often of non-CV causes.  
 
Clinical Trial: NCT00094302, NCT00095238, NCT00634712 
 
CONDENSED ABSTRACT: Limited data is available on age related differences in heart 
failure with preserved ejection fraction(HFpEF) Using data on patients with LVEF{greater than 
or equal to>45% from three large HFpEF trials(TOPCAT, I-Preserve and CHARM-Preserved), 
we compared clinical and echocardiographic characteristics, as well as mortality and 
hospitalization rates, mode of death and quality-of-life across age categories. Younger patients 
with HFpEF were more likely to be obese non-white men with fewer comorbidities. 
Nevertheless, younger patients had worse quality of life and among patients who died, younger 
patients more often died of cardiovascular causes compared to the elderly, particularly sudden 
death. 
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ABBREVIATIONS 
ANOVA: one-way analysis of variance 
ASE: American Society of Echocardiography 
CV: Cardiovascular 
BMI: body mass index 
CHARM: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity 
HFpEF: heart failure with preserved ejection fraction 
I-Preserve: Irbesartan in Heart Failure with Preserved Ejection Fraction trial 
KCCQ: Kansas City Cardiomyopathy Questionnaire 
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LA: left atrial 
LVEF: left ventricular ejection fraction 
LVH: left ventricular hypertrophy 
MLWHFQ: Minnesota Living with Heart Failure questionnaire 
RWT: relative wall thickness 
TOPCAT: Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone 
Antagonist trial 
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Introduction 
Heart failure with preserved ejection fraction (HFpEF) is generally considered a disease 
of the elderly, with the majority of patients >65 years (1, 2). Yet, several studies have reported 
that many patients with HFpEF are younger than this: a study among 2398 patients hospitalized 
with confirmed HFpEF from central Massachusetts, showed that 14.9% of patients were below 
65 years(3). Furthermore, results from the MAGGIC meta-analyses group suggested that 14% of 
all patients with HF below 40 years have HFpEF (4).  
Several studies have investigated differences between age strata for patients with HF(5–
10). Data from the MAGGIC meta-analysis and Candesartan in Heart failure: Assessment of 
Reduction in Mortality and morbidity (CHARM) program, showed that elderly patients with HF 
have higher mortality rates compared to the young(4, 6). However, younger patients with HF had 
worse signs and symptoms and a longer hospital stay. An important limitation of these previous 
studies is that they either included only patients with HFrEF or did not differentiate between 
patients with HFrEF and HFpEF due to unavailability of data on left ventricular ejection fraction 
(LVEF)(6, 9, 10). Two previous studies investigated age related differences in HFpEF, however 
these studies were either restricted to hospitalized patients from a single US state with a limited 
age range and no data on cause-specific outcomes(3), or limited to patients from Asia with scant 
data on clinical outcomes (11). Since age is an important determining factor of HFpEF, more 
data is needed. Therefore, in this study we analyzed differences in clinical and echocardiographic 
characteristics, as well as in clinical outcomes, including mode of death in patients with HFpEF 
across age categories using individual patient data form the three largest HFpEF trials conducted 
to date i.e. CHARM-Preserved, Irbesartan in Heart Failure with Preserved Ejection Fraction trial 
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(I-Preserve) and the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone 
Antagonist trial (TOPCAT).  
Methods 
Patient population 
This study utilized data from CHARM-preserved, I-Preserve and TOPCAT(12–14). 
Briefly, patients enrolled in CHARM-Preserved were ≥18 years, had been in NYHA functional 
class II-IV for at least 4 weeks, and had a prior hospital admission for a cardiac reason and  a 
LVEF >40%(14). I-Preserve included patients ≥60 years in NYHA functional class II-IV, a 
LVEF of ≥45% and echocardiographic, electrocardiographic or radiologic evidence supporting a 
diagnosis of heart failure; patients in NYHA functional class II were also required to have had a 
hospitalization for HF within the previous 6 months(13). TOPCAT included patients ≥50 years 
with at least one symptom and one sign of heart failure, a LVEF of ≥45%, and either a 
hospitalization for HF within the previous 12 months or an elevated natriuretic peptide level 
within 60 days before randomization (B-type natriuretic peptide [BNP] ≥100 pg per milliliter or 
an N-terminal pro-BNP [NT-proBNP] level ≥360 pg per milliliter). We excluded patients with an 
LVEF <45% from CHARM-preserved and patients from Russia and Georgia in TOPCAT 
(n=1678), due to doubts about the reliability of diagnosis of HFpEF(15, 16).  
Echocardiographic sub-study 
Echocardiography was performed in 735 patients in I-Preserve and 654 patients in 
TOPCAT(17, 18). In both studies, LV mass was calculated by the American Society of 
Echocardiography (ASE) recommended formula for estimation of LV mass from LV linear 
dimensions and indexed to body surface area in both studies. The presence of left ventricular 
hypertrophy (LVH) was determined using partition values of LV mass indexed to body surface 
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area ≥115 g/m2 for men and ≥95 g/m2 for women. Concentric remodeling was defined as relative 
wall thickness (RWT) >0.42. LV geometry was determined as normal when RWT ≤0.42 and 
there was no LVH, concentric remodeling: RWT >0.42 and no LVH, eccentric hypertrophy 
RWT ≤0.42 and LVH and concentric hypertrophy RWT>0.42 and LVH. Left atrial (LA) size 
was categorized as mildly enlarged if LA area was 20 to 30 cm2 and moderately-to-severely 
enlarged if LA area was >31 cm2 (17, 18). 
Outcomes 
The primary outcome in the present analysis was all-cause mortality censored at 5 years. 
Secondary outcomes include cause-specific mortality (cardiovascular [CV] vs. non-CV) at 5 
years and hospitalization for HF within 5 years as well as a composite outcome of CV death or 
HF hospitalization within 5 years. Mode/cause of death examined included death due to pump-
failure, sudden death (SD), myocardial infarction, stroke and “other” CV death. All deaths and 
hospitalizations were adjudicated by an independent end-point committee in each trial (the same 
committee in CHARM-Preserved and TOPCAT). Patient self-reported quality of life (QoL) was 
measured using the Minnesota Living with Heart Failure questionnaire (MLWHFQ) in CHARM-
Preserved and I-Preserve and with the Kansas City Cardiomyopathy Questionnaire (KCCQ) in 
TOPCAT; a higher MLWHFQ score indicates worse QoL whereas a lower score represents 
worse QoL using the KCCQ. 
Statistical analysis 
Patients were categorized according to clinical meaningful cutoffs of age, as follows: ≤55 
years, 56-64 years, 65-74 years, 75-84 years and ≥85 years. Differences in baseline 
characteristics between age groups were compared using the chi2 test, a one-way analysis of 
variance (ANOVA) test or the Kruskal-Wallis test where appropriate. Multivariable adjustment 
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included sex, body mass index (BMI) NYHA class, race, history of myocardial infarction, 
diabetes, hypertension, serum creatinine, LVEF and treatment. Since age and sex are already 
included in the multivariable model, we included creatinine to correct for differences in renal 
function rather than eGFR. Incidence rates of all outcomes are presented per 100 person-years. 
Risk of all-cause mortality, cause-specific mortality and HF hospitalizations were estimated as 
hazard ratios in Cox regression analyses. All-cause mortality was used as a competing risk when 
analyzing hospitalizations for HF. When analyzing CV and non-CV mortality, non-CV and 
unknown mortality and CV mortality and unknown mortality respectively were used as 
competing risks. In addition to the previously mentioned variables, multivariable survival 
analyses were corrected for treatment arm. We used restricted cubic splines to model age as a 
continuous variable versus clinical outcome. Lastly, we performed interaction analyses between 
age and BMI for all-cause mortality and the combined outcome of CV mortality or HF 
hospitalization at 5 years. In secondary analyses, we included source trial in our multivariable 
models. Clinical outcomes were assessed by cumulative incidence plots. In addition, because of 
the current guideline definition of HFpEF at LVEF≥50% and the age restriction of I-Preserve, 
we have performed two sensitivity analyses of the echocardiographic data: (1) restricting our 
analyses to patients with LVEF≥50% and (2) reanalyze the echocardiography data according to 4 
subgroups (<65, 75-75, 75-85 and >85 years). All P values are 2 sided, and a value of P<0.05 
was considered significant. All analyses were performed separately with Stata version 15 
(StataCorp, College Station, TX). 
Results 
Baseline characteristics 
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Of the 8461 patients analyzed, 522 were ≤55 (6.2%), 1678 (19.8%) were between 56-64, 
3402 (40.2%) were between 65-74 years, 2461 (29.1%) were between 75-84 years and 398 
(4.7%) were ≥85 years of age. Compared to younger patients, older patients were more often 
white women, with a higher NYHA class, lower eGFR and worse overall signs and symptoms 
(Table 1). Diabetes mellitus, hypertension atrial fibrillation and a previous stroke were more 
prevalent with increasing age, while obesity (body mass index ≥30 kg/m2) was more prevalent 
among younger patients. Younger patients were more often treated with beta-blockers and less 
often with diuretics.  
After correcting for confounders including sex, body mass index (BMI) NYHA class, 
race, history of myocardial infarction, diabetes, hypertension, serum creatinine and LVEF, 
younger patients were more often obese (odds ratio [OR] 1.9; 95%CI 1.7-2.1), men (OR 1.9; 
95%CI 1.7-2.2), and of Asian (OR 2.4; 95%CI 1.4-4.1) or Black (OR 2.8; 95%CI 2.3-3.5) race 
(Figure 1). In contrast, older patients had higher creatinine (OR 0.3 ;95%CI 0.2-0.4) and were in 
a higher NYHA class (NYHA class III/IV, OR 0.9; 95%CI 0.8-0.9, Figure 1).  
Quality of life expressed by the KCCQ score in TOPCAT was worse in younger patients 
with HFpEF (Online Table 1) and a similar association was observed between the MLWHFQ 
score and age in CHARM-preserved (beta coefficient -0.24; P <0.001) and I-Preserve (beta 
coefficient -0.04; P = 0.024). This association remained significant after correction for sex, 
history of atrial fibrillation, diabetes and BMI (P <0.05 for all).  
Echocardiographic Measurements 
Overall, left ventricular (LV) volumes decreased with increasing age (Table 2). Younger 
patients with HFpEF had higher LV mass indexed to BSA compared to the elderly, with higher 
rates of left ventricular hypertrophy (≤55 years; 50% vs 41% in patients ≥85 years, P <0.001) 
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and abnormal relative wall thickness (≤55 years; 86% vs 68% in patients ≥85 years, P <0.001). 
Filling pressures (E/e’) were slightly higher in younger patients (P= 0.022). Atrial size increased 
with increasing age. Overall, younger patients with HFpEF more often had concentric 
remodeling compared to older patients. After correcting for race, sex, BMI and history of 
diabetes, hypertension and atrial fibrillation, older age was associated with similar rates of 
abnormal relative wall thickness (OR 1.01; 95%CI 0.99-1.02) and abnormal filling pressures 
(E/e’ >14; OR 1.01; 95%CI 0.99-1.03) but higher rates of LVH (OR 1.02; 95%CI 1.01-1.04). In 
sensitivity analyses according to 4 age groups (<65, 65-74, 75-84 and ≥85 years) and to patients 
with an LVEF≥50%, results were similar (Online Tables 2 and 3).  
Clinical outcomes 
Overall, 1644 (19%) patients died and 1480 (17%) patients were hospitalized for HF 
within 5 years.  
Mortality: Among patients ≤55, 30 (6%) died after 5 years versus 190 (47%) among 
patients ≥85 years, equating to event rates of 1.9 (95%CI 1.3-2.7) and 16.7 (95%CI 14.5-19.2) 
per 100 patient years, respectively. The unadjusted rates for all-cause mortality, CV-mortality, 
non-CV mortality and hospitalizations for HF were higher in older patients (Table 3, Figure 2). 
Restricted cubic spline analyses for the association between age and all-cause mortality are 
shown in Online Figure 1A. 
After multivariable adjustment, elderly (≥85 years) patients continued to have worse 
outcomes compared to younger patients (≤55 years): hazard ratio [HR] 6.9 (95%CI 4.2-11.4). 
The differential in risk between older and younger patients was greatest non-CV death (HR 10.5; 
95%CI 3.7-29.4), compared with CV death (HR 4.6; 95%CI 2.5-8.4). When investigating causes 
of death, the ratio of non-CV death increased with increasing age (Figure 3). In very young 
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patients (≤55 years), SD was the single most important cause of death. Inclusion of source trial in 
multivariable analyses did not affect our results. 
Composite of CV mortality/HF hospitalization: Among patients ≤55, 76 (15%) died or 
were admitted to hospital with worsening heart failure after 5 years versus 163 (41%) among 
patients ≥85 years, equating to event rates of 5.3 (95%CI 4.3-6.6) and 19.1 (95%CI 16.6-22.1) 
per 100 patient years, respectively. After multivariable correction, patients aged ≥85 years (SHR 
2.1; 95%CI 1.5-2.9) had higher composite event rates in 5 years compared to patients aged ≤55 
(Table 3). A restricted cubic spline analysis for the association between age and the composite 
outcome of CV mortality or HF hospitalization is shown in Online Figure 1B. 
Hospitalization for HF: In total, 59 (11%) of patients ≤55 years were hospitalization for 
HF within 5 years compared to 115 (29%) of patients ≥85 years. This equates to event rates of 
4.0 (95%CI 3.1-5.1) and 12.0 (95%CI 10.0-14.4) per 100 patient years for patients ≤55 and ≥85 
years respectively. A more u-shaped association appeared after multivariable adjustment, where 
patients 56-64 years were hospitalization for HF less often (SHR 0.7; 95%CI 0.5-0.9) and 
patients ≥85 years were hospitalized for HF more often (SHR 1.7; 9%CI 1.2-2.5). A restricted 
cubic spline analysis of the association between age and HF hospitalization is shown in Online 
Figure 1C. 
Interaction with obesity: A significant interaction was found between age and BMI for 
both all-cause mortality and the composite outcome of CV mortality or HF hospitalization in 
univariable and multivariable analyses (Pinteraction for all <0.05). Obesity (BMI≥30 kg/m
2) was 
associated with lower rates of all-cause mortality in patients ≥65 years (HR 0.8; 95%CI 0.7-0.9), 
but not in patients <65 years (HR 1.4; 95%CI 1.1-1.8). Similarly, obesity was associated with 
higher rates of the combined outcome in patients <65 years (SHR 2.0; 95%CI 1.6-2.5), but not in 
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patients ≥65 years (SHR 1.0; 95%CI 0.9-1.1). Obesity remained significantly associated with 
higher rates of the composite outcome after multivariable correction for sex, creatinine, ethnicity, 
NYHA class, diabetes, hypertension, atrial fibrillation, LVEF and treatment arm (SHR 1.3; 
95%CI 1.1-1.7) in patients <65 years, but not in patients ≥65 years (SHR 0.9; 95%CI 0.9-1.1). 
Discussion 
Younger patients with HFpEF were more often obese Black or Asian men with a lower 
comorbidity burden, yet had worse quality of life compared to older patients with HFpEF. Older 
patients with HFpEF were more often white women and had a higher comorbidity burden 
compared to younger patients. Non-CV death was a more important cause of death in elderly 
patients with HFpEF. In contrast, younger patients with HFpEF died more of CV causes, with 
SD being the most common cause of death.  
Younger patients had a distinct clinical profile compared to older patients. In particular, 
younger patients were more than twice as likely to be obese compared to elderly patients, 
suggesting a predominant role of obesity in the pathogenesis of HFpEF in the young. 
Importantly, a recent study by Obokata et al. showed that obesity is a “true” HFpEF phenotype. 
Moreover, these obese patients were considerably younger than non-obese HFpEF patients(19). 
Similar results were also seen in ASIAN-HFpEF—younger patients were more often obese, 
while older patients had a higher comorbidity burden, particularly atrial fibrillation and worse 
renal function, which is also consistent with data from Massachusetts (3, 20). Our study extends 
the findings in the previous studies on HFpEF in the young from Asia and Massachusetts  in 
several important ways including: (1) it is the first global multinational study of HFpEF in the 
young;(2) by having large numbers of adjudicated outcomes over long-term follow up we were 
able to examine mode of death; (3) we describe patient-reported quality of life measures and (4) 
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we report age-related differences in echocardiographic data on cardiac structure and function. 
Together with previous data, our study suggests a potential dichotomization of HFpEF 
phenotypes, with young obese HFpEF vs elderly HFpEF with a higher comorbidity load. That 
young obese HFpEF is a “true” HFpEF phenotype, is further supported by the increased LV 
volumes and increased prevalence of concentric remodeling in younger patients support the 
presence of adverse load following obesity and excess hypervolemia from plasma volume 
expansion (19, 20) as well as data from Olmsted County showing that obese patients with 
HFpEF were younger than non-obese patients with HFpEF(19, 21). Importantly, the latter study 
clearly demonstrated that these obese patients had “true” HFpEF, with raised left ventricular 
filling pressures in spite of lower NT-proBNP levels, and evidence of volume overload(19, 21). 
A separate prospective study from the Swedish Conscript Registry showed that obesity in early 
adulthood is associated with an increased risk for early onset HF. While the type of HF was not 
characterized in that study, our data suggest that an important proportion of those cases might 
have been HFpEF(22). Moreover, obesity as a risk factor for developing HF at a young age 
seems to be even more important in individuals of non-white ancestry, which is in line with our 
findings(23). This is further supported by the significant interaction between obesity and age for 
the composite outcome, where obesity was associated with worse clinical outcomes in younger, 
but not in older patients. In one small HFpEF study, each of caloric restriction and aerobic 
exercise training increased peak oxygen consumption. In addition, quality of life as measured by 
KCCQ improved in the diet arm, however the primary quality of life measure MLWHFQ did not 
improve with both exercise and diet (24). Beyond obesity, younger patients more often had DM 
independent of BMI compared to older patients. This suggests that beyond obesity alone, 
metabolic derangements following diabetes might be a possible risk factor for developing 
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HFpEF at a younger age. The link of obesity to diabetes, and the strong relationship of diabetes 
with worse outcome in HF, may be another important dimension of obesity in HF.  
Younger patients with HFpEF had less objective evidence of fluid overload and were less 
often treated with diuretics despite having higher filling pressures (E/e’). Younger patients with 
HFrEF also show fewer signs of congestion (peripheral edema and basilar pulmonary crackles) 
and are less likely to be treated with diuretics. This may indicate that that fluid extravasation 
from the intravascular compartment does not occur as easily in younger compared with older 
patients with heart failure. However, a raised jugular venous pressure is reported as commonly in 
younger as older patients with HFrEF(6). This may mean that it is especially difficult to measure 
the jugular venous pressure in obese patients with HFpEF and echocardiographic measurement 
of filling pressures may be a particularly important tool in these patients for both diagnosis and 
clinical follow-up. In addition, younger patients with HFpEF might only display increased filling 
pressures at exertion (19), which emphasizes the importance of obesity as a risk factor for 
HFpEF and suggests that also exercise testing is of importance in these patients 
Younger patients were less likely to be white compared to the elderly, although most 
patients in all age groups were white. This finding is in line with a recent report from the Asian 
Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry, showed that Asian patients with 
HF are more than a decade younger than their western counterparts (11, 25, 26). In a particular 
study from ASIAN-HF investigating age-related differences in HFpEF, younger patients were 
more often obese men of Malay or Indian ethnicity. Furthermore, younger patients had similar 
cardiac structure and function, had better survival and similar quality of life compared to older 
patients (11). Our results confirm that ethnicity, sex and obesity play an important role in the 
young HFpEF phenotype. In addition, our study extends upon these previous findings by 
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showing that CV causes of death, particularly sudden death, is more important in younger 
patients with HFpEF. Furthermore, this previous study only included only patients from Asia. In 
contrast to ASIAN-HF, younger patients in our study had a higher prevalence of concentric 
hypertrophy and worse diastolic dysfunction compared to the elderly. This might be explained by 
the relatively large proportion of black patients among young patients with HFpEF; black 
patients have a higher afterload sensitivity as a stimulus for LV structural and functional 
remodeling, leading to greater diastolic dysfunction and more adverse remodeling (27). Indeed, 
this might explain the fact that incident HF before 50 years is more common among blacks 
compared to whites in the United States (23). Additional reports from the African continent 
described that African patients with HF are generally younger and more often have a 
hypertensive etiology of HF, suggesting that HFpEF has a potential higher prevalence in Africa 
(28–30).  
When looking at quality of life, elderly patient had better quality of life compared to the 
younger patients, while there were no age related differences observed in quality of life across 
age strata in ASIAN-HF, power was considerably lower in the latter study (11). Several studies 
have reported that quality of life in HF varies by region (31, 32), ethnicity (33) and 
socioeconomic status (33, 34), which might explain the differences in association between age 
and quality of life in ASIAN-HF where patients were exclusively from Asia and the present 
study. Furthermore, our results are in line with a multinational study from the CHARM program, 
which reported similar differences in quality of life across age-strata in a combined cohort of 
patients with HFrEF and HFpEF (6). Perhaps some the most interesting findings in our study is 
the difference in mortality across age groups. Overall, older patients with HFpEF had higher 
mortality rates than younger patients. However, while the absolute mortality rate was lower in 
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younger patients with HFpEF, among patients who died younger patients with HFpEF died 
proportionally more frequently of CV causes than the elderly. Compared to HFrEF, patients with 
HFpEF are older and die more often from non-CV related causes(35–37). Indeed, age is an 
important predictor of non-CV death, compared with CV-death, in HF(38). Furthermore, older 
patients had a higher comorbidity burden, which might explain the higher proportion of non-CV 
death. In contrast to the elderly, younger patients with HFpEF died more of CV related causes, 
and particularly SD. However, without a terminal ECG rhythm strip it is not possible to 
differentiate sudden cardiac death (SCD) from other types of SD in this population e.g. 
cerebrovascular accident(36). A previous analysis of the DANISH study found that younger 
patients with non-ischemic HFrEF derived more benefit from cardiac defibrillator 
implantation(39). Similarly, a post-hoc analysis of the Surgical Treatment for Ischemic Heart 
Failure (STICH) trial, showed that particularly younger patients with HFrEF benefited more 
from coronary artery bypass grafting added to medical therapy compared to the elderly(40). 
Although both the DANISH and STICH trials did not include HFpEF, our current results suggest 
that the concept that younger patients might benefit from cardiovascular interventions deserves 
consideration in younger patients with HFpEF as well. Particularly, while the absolute event rate 
is lower in younger patients with HFpEF compared to the elderly, the number of life-years lost is 
considerably greater in the young. 
Limitations 
Our study has several limitations. First, this was a retrospective analysis. Secondly, we 
used clinical trial data and the patients enrolled were selected compared to patients with HFpEF 
more generally. Associations of age, other characteristics, and outcomes may or may not be 
causally linked. Importantly, I-Preserve and TOPCAT had lower age limits of 60 and 50 years, 
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respectively that might have underestimated the proportion of younger HFpEF patients in our 
analysis. The majority of our study population was of white ethnicity. It is not clear whether our 
results are generalizable to other ethnicities and more studies in non-white populations are 
needed. Lastly, data included in this study are from clinical trials and may not be representative 
of real-world HFpEF populations. 
Conclusions 
Patients with a HFpEF show distinct age dependent clinical profiles. Whereas younger 
patients are often obese non-white men, elderly patients are more often women with a plethora of 
comorbidities. Young patients die more of CV causes, particularly SD, while elderly patients die 
more from non-CV causes. Interventional trials targeting obesity and the prevention of sudden 
cardiac death may be of particular interest in younger patients with HFpEF. 
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PERSPECTIVES 
Competency in Medical Knowledge: Younger patients with HFpEF are more often obese, non-
white men, while older patients are more often white women with a higher prevalence of 
comorbidities. Despite fewer comorbidities, younger patients have worse quality of life, 
compared with older patients. Younger patients experienced proportionally more cardiovascular 
mortality and sudden death was the most common mode of death in younger patients.  A higher 
proportion of older patients died from non-cardiovascular causes. 
Translational Outlook: The global increase in obesity has major implications for the future risk 
of HFpEF at a younger age in Black and Asian populations. In addition to efforts to reduce 
obesity, specific therapies targeted at the risk of HFpEF in obese individuals are needed. 
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Figure Legends 
Figure 1: Forest plot depicting association between baseline clinical characteristics and 
odds of being <65 years versus ≥65 years. Clinical characteristics with a mean odds ratio and 
lower confidence bound >1 are significantly associated with being <65 years, while clinical 
characteristics with a mean odds ratio and lower confidence bound <1 are associated with being 
≥65 years. Abbreviations: LVEF, left ventricular ejection fraction; NYHA, New York heart 
association. 
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Figure 2: Cumulative incidence curves for all-cause mortality (A), CV mortality (B), a 
composite outcome of CV mortality or hospitalization for HF (C) and non-CV mortality 
(D)  by age strata. Abbreviations: CV, cardiovascular; HF, heart failure.  
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Figure 3: Stacked bar graph showing adjudicated causes of death among patients who died 
across age strata. Abbreviations: CV, cardiovascular; HF, heart failure; MI, myocardial 
infarction. 
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Figure 4: Central illustration describing age related differences in patients with HFpEF. 
Abbreviations: CV, cardiovascular.
 
  
27 
Table 1: Baseline characteristics  
 
≤55 56-64 65-74 75-84 ≥85 p-
valu
e 
N 522 1679 3405 2464 398 
 
Demographics 
      
Age (years) 49.9 (5.1) 61.1 (2.3) 69.6 (2.9) 78.6 (2.7) 87.2 (2.1) NA 
male 336 (64.4%) 928 (55.3%) 1555 
(45.7%) 
1039 
(42.2%) 
152 (38.2%) <0.0
01 
NYHA 
      
 II 285 (68.3%) 529 (40.4%) 993 (34.8%) 580 (31.0%) 73 (29.8%) <0.0
01 
 III 128 (30.7%) 757 (57.8%) 1812 
(63.4%) 
1227 
(65.6%) 
161 (65.7%) 
 
 IV 4 (1.0%) 24 (1.8%) 53 (1.9%) 63 (3.4%) 11 (4.5%) 
 
Race 
      
 White 408 (78.2%) 1444 
(86.0%) 
3093 
(90.8%) 
2282 
(92.6%) 
369 (92.7%) <0.0
01 
 Black 85 (16.3%) 139 (8.3%) 162 (4.8%) 92 (3.7%) 14 (3.5%) 
 
 Asian 15 (2.9%) 33 (2.0%) 41 (1.2%) 21 (0.9%) 8 (2.0%) 
 
 Other 14 (2.7%) 63 (3.8%) 109 (3.2%) 69 (2.8%) 7 (1.8%) 
 
BMI 33.1 (8.2) 32.0 (7.2) 30.6 (5.9) 29.0 (5.6) 27.0 (5.3) <0.0
01 
Heart rate 72.7 (12.3) 71.1 (11.2) 70.5 (11.2) 71.1 (11.5) 70.6 (11.6) <0.0
01 
eGFR 86.3 (29.8) 78.1 (24.4) 71.5 (21.9) 63.9 (20.3) 57.2 (19.3) <0.0
01 
LVEF 56.0 (8.3) 57.4 (8.7) 58.4 (8.8) 58.6 (8.9) 59.5 (8.8) <0.0
01 
Signs and 
symptoms 
      
Shortness of 
breath 
481 (92.1%) 1508 
(94.9%) 
2999 
(94.2%) 
2177 
(94.4%) 
344 (93.7%) 0.22 
Rales 52 (10.0%) 305 (18.3%) 787 (23.2%) 613 (25.0%) 106 (26.8%) <0.0
01 
Increased JVP 47 (9.2%) 131 (7.9%) 289 (8.6%) 301 (12.4%) 70 (17.9%) <0.0
01 
Peripheral 
edema 
181 (34.7%) 835 (49.8%) 1751 
(51.4%) 
1308 
(53.0%) 
216 (54.3%) <0.0
01 
Medical history 
      
BMI 
      
<18.5 1 (0.2%) 5 (0.3%) 12 (0.4%) 20 (0.8%) 11 (2.8%) <0.0
01 
18.5-25 63 (12.1%) 213 (12.7%) 480 (14.1%) 538 (22.0%) 146 (40.0%) 
 
25-30 167 (32.1%) 538 (32.1%) 1323 
(38.9%) 
963 (39.4%) 146 (36.7%) 
 
28 
>30 290 (56%) 918 (54.9%) 1582 
(46.6%) 
924 (37.8%) 93 (23.5%) 
 
>35 167 (32.1%) 442 (26.4%) 678 (20.0%) 326 (13.4%) 31 (7.9%) <0.0
01 
PCI/CABG 140 (26.8%) 456 (27.2%) 706 (20.7%) 574 (23.2%) 68 (17.1%) <0.0
01 
Myocardial 
infarction 
182 (34.9%) 499 (29.8%) 952 (27.9%) 677 (27.4%) 74 (18.6%) <0.0
01 
eGFR<60 48 (17.0%) 324 (25.1%) 928 (33.4%) 931 (45.2%) 195 (59.8%) <0.0
01 
Diabetes 
mellitus 
165 (31.6%) 625 (37.3%) 1083 
(31.8%) 
706 (28.6%) 74 (18.6%) <0.0
01 
Valvular 
disease 
7 (1.7%) 61 (4.7%) 193 (6.8%) 230 (12.3%) 40 (16.3%) <0.0
01 
Hypertension 353 (67.6%) 1350 
(80.4%) 
2900 
(85.2%) 
2021 
(82.0%) 
306 (76.9%) <0.0
01 
Atrial 
fibrillation 
81 (15.5%) 350 (20.8%) 1057 
(31.0%) 
1048 
(42.5%) 
185 (46.5%) <0.0
01 
Stroke or Tia 32 (6.1%) 110 (6.6%) 326 (9.6%) 264 (10.7%) 47 (11.8%) <0.0
01 
Medication 
      
Beta-blocker 332 (63.6%) 1159 
(69.1%) 
2126 
(62.5%) 
1416 
(57.5%) 
199 (50.0%) <0.0
01 
Calcium 
channel blocker 
160 (30.7%) 660 (39.4%) 1306 
(38.4%) 
895 (36.4%) 135 (33.9%) 0.00
1 
Diuretic 355 (68.0%) 1297 
(77.3%) 
2801 
(82.4%) 
2111 
(85.8%) 
351 (88.2%) <0.0
01 
Laboratory 
      
Potassium 
(mmoL/L) 
4.1 (3.8, 4.3) 4.3 (4.0, 4.6) 4.4 (4.1, 4.7) 4.3 (4.0, 4.7) 4.3 (4.0, 4.6) <0.0
01 
Sodium (mEq/L) 139.0 (138.0, 
141.0) 
140.0 (138.0, 
142.0) 
140.0 (138.0, 
141.0) 
140.0 (138.0, 
141.0) 
140.0 (138.0, 
142.0) 
0.15 
Creatinine 
(mg/dL) 
0.9 (0.8, 1.2) 0.9 (0.8, 1.2) 1.0 (0.8, 1.2) 1.1 (0.9, 1.3) 1.2 (0.9, 1.4) <0.0
01 
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Table 2: Echocardiographic characteristics 
 
≤55 56-64 65-74 75-84 ≥85 p-
valu
e 
LV dimensions 
      
LVEDV 112.8 (84.9, 
140.8) 
100.9 (79.4, 
125.4) 
90.1 (68.5, 
112.0) 
83.2 (64.2, 
104.8) 
81.6 (64.2, 
109.0) 
<0.0
01 
LVESV 44.0 (32.2, 
58.0) 
37.5 (27.6, 
49.1) 
32.7 (23.4, 
43.8) 
29.5 (22.2, 
42.3) 
30.7 (24.3, 
44.8) 
<0.0
01 
LVS 1.2 (1.1, 1.4) 1.1 (0.9, 1.3) 1.0 (0.9, 1.2) 1.0 (0.9, 1.2) 1.1 (1.0, 1.3) <0.0
01 
PWT 1.2 (1.1, 1.3) 1.0 (0.9, 1.2) 1.0 (0.9, 1.1) 1.0 (0.9, 1.2) 1.0 (1.0, 1.2) <0.0
01 
Lvmass 222.9 
(183.6, 
280.6) 
199.5 
(147.2, 
254.4) 
175.4 
(139.9, 
222.4) 
179.6 
(144.8, 
222.9) 
173.4 
(151.8, 
219.7) 
<0.0
01 
Lvmassi 103.8 (84.8, 
123.6) 
94.4 (76.8, 
116.2) 
91.7 (75.1, 
110.5) 
97.4 (80.5, 
117.9) 
97.7 (82.8, 
120.3) 
0.002 
Lvmassi* 54.7 (45.5, 
67.4) 
48 (37.2, 
60.3) 
45.1 (36.6, 
54.9) 
46.5 (38.6, 
58.8) 
47.9 (37.9, 
55.1) 
<0.0
01 
 LVH (%) 50 35 32 42 41 0.006 
LVH (%)*  74 54 49 51 52 <0.0
01 
RWT 0.5 (0.4, 0.6) 0.4 (0.4, 0.5) 0.4 (0.4, 0.5) 0.4 (0.4, 0.5) 0.5 (0.4, 0.5) <0.0
01 
 RWT>0.42 (%) 86 60 49 57 68 <0.0
01 
LVEF 55.0 (50.0, 
60.0) 
56.0 (50.0, 
63.0) 
58.0 (51.0, 
64.0) 
58.0 (51.0, 
65.0) 
60.0 (53.0, 
65.0) 
<0.0
01 
Diastolic 
dysfunction 
      
Ewave 93.6 (67.0, 
112.9) 
83.7 (64.1, 
108.1) 
78.6 (60.9, 
99.8) 
82.9 (65.1, 
101.5) 
81.4 (66.6, 
97.9) 
0.033 
Awave 68.3 (46.5, 
83.4) 
74.1 (59.2, 
89.1) 
80.6 (64.4, 
96.0) 
82.6 (61.5, 
100.8) 
80.5 (54.8, 
97.5) 
<0.0
01 
E/e' lateral 14.1 (8.7, 
16.9) 
9.8 (7.3, 
13.1) 
9.4 (7.3, 
12.2) 
9.7 (7.3, 
13.1) 
10.0 (7.7, 
14.1) 
0.022 
EA ratio 1.4 (1.0, 2.0) 1.0 (0.8, 1.5) 0.9 (0.7, 1.2) 0.9 (0.7, 1.4) 0.9 (0.7, 1.5) <0.0
01 
LAA 17.7 (15.7, 
20.9) 
20.2 (16.0, 
24.2) 
21.1 (17.5, 
24.9) 
22.1 (18.2, 
25.7) 
20.8 (17.8, 
24.0) 
<0.0
01 
Geometry 
     
<0.0
01 
 Normal (%) 10 31 38 30 26 
 
 Concentric 
remodeling (%) 
41 34 30 28 33 
 
 Concentric 
hypertrophy (%) 
45 26 20 29 36 
 
30 
 Eccentric 
hypertrophy (%) 
5 9 12 13 5 
 
*LVmass indexed to height to the power of 1.7 
  
31 
Table 3: Association between age and outcomes (all-cause mortality, cardiovascular (CV) mortality, 
non-CV mortality and CV mortality or HF hospitalization). 
      All-cause mortality 
      Univariable Model 1 Model 2 
  
Cases/
N 
Events/100 pt yrs 
(95%CI) 
HR (95%CI) p-
value 
HR (95%CI) p-
value 
HR (95%CI) p-
value 
≤55 30/522 1.89 (1.32-2.70) reference reference reference 
56-
64 
187/16
78 
3.21 (2.78-3.70) 
1.62 (1.10-2.39) 
0.014 
1.58 (0.97-2.58) 
0.068 
1.60 (0.98-2.62) 
0.059 
65-
74 
601/34
05 
4.89 (4.51-5.30) 
2.45 (1.70-3.54) 
<0.001 
2.22 (1.38-3.57) 
0.001 
2.28 (1.42-3.68) 
0.001 
75-
84 
636/24
64 
7.63 (7.01-7.24) 
3.86 (2.68-5.57) 
<0.001 
3.15 (1.94-5.08) 
<0.001 
3.15 (1.95-5.08) 
<0.001 
≥85 
190/39
8 
16.74 (14.52-19.29) 
8.72 (5.93-12.82) 
<0.001 
6.48 (3.93-10.69) 
<0.001 
6.89 (4.17-11.37) 
<0.001 
      CV mortality 
≤55 23/522 1.45 (0.96-2.18) reference reference reference 
56-
64 
133/16
79 
2.28 (1.93-2.70) 
1.53 (0.98-2.38) 
0.062 
1.48 (0.82-2.65) 
0.183 
1.49 (0.83-2.66) 
0.182 
65-
74 
414/34
05 
3.38 (3.07-3.72) 
2.22 (1.46-3.38) 
<0.001 
1.96 (1.11-3.44) 
0.020 
2.00 (1.13-3.52) 
0.017 
75-
84 
414/24
64 
4.83 (4.38-5.32) 
3.12 (2.05-4.76) 
<0.001 
2.48 (1.41-4.38) 
0.002 
2.39 (1.35-4.24) 
0.003 
≥85 
125/39
8 
10.74 (9.00-12.83) 
6.58 (4.21-10.28) 
<0.001 
4.45 (2.46-8.08) 
<0.001 
4.62 (2.53-8.44) 
<0.001 
      Non-CV mortality 
≤55 6/522 0.38 (0.17-0.84) reference reference reference 
56-
64 
49/167
9 
0.84 (0.63-1.11) 
2.12 (0.91-4.94) 
0.083 
1.96 (0.70-5.52) 
0.200 
1.98 (0.70-5.55) 
0.196 
65-
74 
176/34
05 
1.43 (1.23-1.65) 
3.50 (1.55-7.91) 
0.003 
3.01 (1.10-8.21) 
0.032 
3.04 (1.11-8.29) 
0.030 
75-
84 
216/24
64 
2.58 (2.26-2.95) 
6.19 (2.74-13.94) 
<0.001 
4.95 (1.81-13.52) 
0.002 
4.87 (1.79-13.27) 
0.002 
≥85 64/398 5.64 (4.41-7.20) 
12.31 (5.33-28.48) 
<0.001 
10.71 (3.81-30.12) 
<0.001 
10.45 (3.72-29.35) 
<0.001 
   Hospitalization for HF 
≤55 59/522 4.00 (3.07-5.12) reference reference reference 
56-
64 
199/16
79 
3.64 (3.17-4.18) 
0.97 (0.73-1.30) 
0.853 
0.75 (0.54-1.03) 
0.071 
0.70 (0.50-0.95) 
0.024 
65-
74 
535/34
05 
4.74 (4.35-5.16) 
1.26 (0.96-1.65) 
0.090 
0.94 (0.70-1.28) 
0.723 
0.87 (0.64-1.17) 
0.368 
75-
84 
572/24
64 
7.79 (7.18-8.45) 
1.97 (1.51-2.57) 
<0.001 
1.39 (1.02-1.88) 
0.035 
1.24 (0.91-1.68) 
0.173 
≥85 
115/39
8 
11.98 (9.98-14.38) 
2.66 (1.94-3.65) 
<0.001 
1.78 (1.23-2.56) 
0.002 
1.70 (1.18-2.46) 
0.005 
      CV-mortality or hospitalization for HF 
32 
≤55 79/522 5.31 (4.26-6.63) reference reference reference 
56-
64 
268/16
79 
5.23 (4.66-5.88) 
1.02 (0.79-1.31) 
0.900 
0.80 (0.60-1.07) 
0.129 
0.77 (0.58-1.02) 
0.070 
65-
74 
792/34
05 
7.02 (6.54-7.52) 
1.36 (1.08-1.72) 
0.009 
1.03 (0.79-1.35) 
0.821 
0.99 (0.75-1.30) 
0.921 
75-
84 
790/24
64 
10.76 (10.03-11.53) 
2.02 (1.60-2.54) 
<0.001 
1.40 (1.06-1.84) 
0.016 
1.30 (0.98-1.71) 
0.066 
≥85 
184/39
8 
19.17 (16.59-22.14) 
3.35 (2.57-4.36) 
<0.001 
2.11 (1.54-2.89) 
<0.001 
2.10 (1.53-2.90) 
<0.001 
      Sudden death 
≤55 13/522 0.82 (0.48-1.41) reference reference reference 
56-
64 
51/167
9 
0.88 (0.67-1.15) 
1.05 (0.57-1.93) 
0.882 
1.32 (0.52-3.37) 
0.563 
1.34 (0.52-3.43) 
0.539 
65-
74 
173/34
05 
1.41 (1.22-1.64) 
1.66 (0.94-2.92) 
0.079 
2.14 (0.87-5.29) 
0.099 
2.26 (0.91-5.60) 
0.078 
75-
84 
124/24
64 
1.49 (1.25-1.77) 
1.67 (0.94-3.00) 
0.078 
1.99 (0.80-4.95) 
0.137 
2.10 (0.84-5.24) 
0.110 
≥85 36/398 3.17 (2.29-4.39) 
3.12 (1.66-5.89) 
<0.001 
3.55 (1.36-9.27) 
0.010 
4.07 (1.55-10.67) 
0.004 
Model 1: Sex, BMI, creatinine, race, NYHA class 
Model 2: Model 1 + diabetes, atrial fibrillation, hypertension, LVEF and treatment arm 
